University at Albany researchers at the RNA Institute are pioneering new methods for designing and assembling DNA ...
But real lightning would have struck infrequently—and mostly in open ocean, where organic compounds would have quickly ...
While initial study results suggest Beam's technology can correct alpha-1 antitrypsin deficiency's genetic roots, shares fell ...
Armed with new proof-of-concept data showing that its in vivo base-editing therapy BEAM-302 can correct the gene mutation in ...
Assembling DNA nanostructures at more moderate temperatures opens up the possibility of using the structures in biomedical ...
The author is looking forward to seeing how Beam Therapeutics would do in their clinical trials of single-base DNA editing.
A new review article highlights the transformative role of circular RNA (circRNA) in cancer, revealing its potential as both ...
Dealbreaker on MSN4d
Beam Base Editor’s Early Data in Rare Liver Disease Tee Up $500M Stock Sale in Tough MarketA Beam Therapeutics gene-editing therapy designed to fix a mutation at the root of a rare liver protein deficiency now has ...
Beam Therapeutics announced positive initial data for BEAM-302 in the Phase I/II trial in Alpha-1 Antitrypsin Deficiency (AATD).
A new method for mapping torsion provides insights into the ways that the genome responds to the torsion generated by RNA polymerase II.
"A key feature of NuFold is how it represents RNA internally, considering the base pairs that are pivotal to the structure while accurately capturing RNA's inherent flexibility. In benchmark tests ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback